Standard BioTools Inc. (LAB) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Standard BioTools Inc. is a life science tools company providing instrumentation, consumables, and services for proteomics and genomics. A material development during the period was the classification of the SomaScan Business (SomaLogic and Sengenics) as discontinued operations following an agreement to sell these assets to Illumina, Inc. for up to $425 million. The transaction is expected to close in the first half of 2026. The Company has reorganized its reporting to reflect a single operating segment (consolidated company) for continuing operations.
Key Financial Metrics (Continuing Operations)
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $19.6M | $22.1M | $61.5M | $66.2M |
| Gross Profit | $9.5M | $12.1M | $31.2M | $33.5M |
| Gross Margin | 48.5% | 54.9% | 50.6% | 50.6% |
| Net Loss (Continuing Ops) | $(31.7M) | $(21.9M) | $(72.7M) | $(63.8M) |
| Net Loss (Total) | $(34.7M) | $(26.9M) | $(94.2M) | $(104.8M) |
| Cash & Investments | $214.4M | $292.9M | $214.4M | $292.9M |
| Operating Cash Flow (9M) | $(73.2M) | $(129.4M) | $(73.2M) | $(129.4M) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for continuing operations decreased 11% in Q3 and 7% for the nine months ended September 30, 2025, compared to the prior year. This was driven by a 17% drop in consumables revenue and a 9% drop in services revenue, attributed to macroeconomic pressures and constrained customer funding.
- Restructuring Charges: Restructuring and related charges increased significantly to $9.4M in Q3 (vs. $2.3M in Q3 2024) and $12.7M for the nine months (vs. $12.4M). This reflects a reduction in force impacting approximately 20% of the global workforce and the consolidation of R&D capabilities from South San Francisco to Singapore.
- Discontinued Operations: The SomaScan Business, previously a major revenue driver, is now reported as discontinued. It generated $26.7M in revenue for Q3 2025 but resulted in a net loss of $3.0M for the quarter.
- Transaction Expenses: Transaction and integration expenses dropped 99% in Q3 to $43K (from $5.1M in Q3 2024) as the SomaLogic merger integration costs from the prior year were one-time in nature.
Guidance, Outlook, and Risks
- Strategic Shift: Management is executing a plan to improve operational efficiency and reduce costs, including relocating the headquarters to Boston, Massachusetts, by December 31, 2025.
- Liquidity: The Company holds $214.4M in cash, cash equivalents, and investments. Management expects these resources to be sufficient to support operations for at least the next 12 months.
- Divestiture: The sale of the SomaScan Business to Illumina is subject to regulatory approval (Hart-Scott-Rodino) and is expected to close in H1 2026. The deal includes an upfront payment of $350M and up to $75M in earnouts.
- Risks: Key risks include the uncertainty of the Illumina transaction closing, ongoing macroeconomic pressures affecting customer spending, and the execution of the restructuring plan. The Company also faces ongoing litigation regarding the SomaLogic merger and Palamedrix milestone payments.
Investor Verification Checklist
- Transaction Closing: Verify the status of the Hart-Scott-Rodino waiting period and the likelihood of the Illumina transaction closing in H1 2026.
- Restructuring Execution: Monitor the timeline for the headquarters relocation to Boston and the completion of the 20% workforce reduction to assess cost savings.
- Continuing Operations Revenue: Assess whether the decline in consumables and services revenue stabilizes as the Company adjusts to the post-SomaScan business model.
- Liquidity Runway: Confirm that the $214.4M cash balance remains sufficient given the continued operating losses in continuing operations.
- Legal Proceedings: Review updates on the SomaLogic stockholder litigation and the Palamedrix milestone dispute to evaluate potential financial exposure.